| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
STRASBOURG
, France—Jan. 17 saw the announcement by DomainTherapeutics that it has entered into an exclusive development and licensingagreement with Merck Serono, a division of Merck KGaA in Darmstadt, Germany, to develop metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) drugs targeting Parkinson's disease and otherneurodegenerative diseases.
 
 
Domain Therapeutics will contribute optimizedcompounds that have been developed from its proprietary chemical series. Underthe terms of the agreement, the company will receive €2 million in upfrontpayment and research funding, and is eligible for up to €132 million inmilestones for the first two products, as well as undisclosed royalties.
 
 
"This agreement is a validation of DomainTherapeutics' business model of addressing difficult GPCRs and partneringcompounds, with a significant deal, at an early stage of development," saysPascal Neuville, CEO of Domain Therapeutics. "Merck Serono is known to set veryhigh standards for the compounds it is licensing and this deal is ademonstration of the quality of our work. We anticipate that this agreementwill enable us to sign further deals of this kind."
 
 
"We are pleased to have the opportunity towork with Domain Therapeutics, which has developed great expertise in the GPCRarea," says Bernhard Kirschbaum, executive vice president for global research and development at Merck Serono. "This partnership with DomainTherapeutics reflects our long-term commitment to develop new treatments forneurodegenerative diseases." 
 
A glutamate receptor, mGluR4 is a member of theG-Protein Coupled Receptor (GPCR) family and is believed to be a potentialtherapeutic target for Parkinson's disease. Allosteric modulation of mGluR4receptors is thought to exert regulatory activity on glutamate-mediatedneurotransmission. 

About the Author

Related Topics

Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue